A team led by Thomas B. Nutman, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has completed a large-scale analysis of most of the proteins produced by Brugia malayi, one kind of parasitic worm that causes lymphatic filariasis, or elephantiasis. The greatly swollen lower limbs that can result from chronic infection with this mosquito-borne parasite can be severely disabling.
The investigators characterized 7,103 proteins produced in various stages of the worm's lifecycle, including male and female adult forms that live in the body's lymphatic system; asexual stages that circulate in human blood; and the larval stage that first infects humans.
The nature and relative amounts of proteins produced during successive stages of the worm's lifecycle provide clues to their likely importance in creating and maintaining infection. For example, proteins made in abundance by larval worms might serve as targets for developing vaccines to prevent infections. Proteins made in large amounts by adult worms might serve as targets for developing drugs to treat infections and potentially halt transmission of the parasite from an infected person to a potential mosquito carrier.
In addition to identifying the worm-made proteins, the team also characterized most of the proteins made by Wolbachia, bacteria that live inside B. malayi. Human inflammatory immune responses to the combined presence of Wolbachia and B. malayi are thought to be responsible for many symptoms of lymphatic filariasis.
Sequencing of the B. malayi genome, which enabled this research on the worm's proteins to be carried out, was completed by National Institutes of Health-funded researchers in 2007.
The above post is reprinted from materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.
Cite This Page: